Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pathologic Processes
Open-data reference.
14 US clinical trials · 2 currently recruiting
Active & Recent Trials
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
C5 Biomedical
NCT06674980
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Brigham and Women's Hospital
NCT06252129
Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
University of Colorado, Denver
NCT04534959
Strategy to Avoid Excessive Oxygen in Major Burn Patients
University of Colorado, Denver
NCT04534972
Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention
University of Colorado, Denver
NCT06374225
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
University of Rochester
NCT04922281
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Cumberland Pharmaceuticals
NCT02682511
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Cancer Institute (NCI)
NCT05797246
Pivotal Study for Validation of Philips Dx (PDx)
Philips Digital & Computational Pathology
NCT02529137
pRESET for Occlusive Stroke Treatment
phenox
NCT03994822
Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00776412
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
Indiana University
NCT02685098
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Dragonfly Research
NCT04837651
Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and Their Caregivers
University of North Carolina, Chapel Hill
NCT05887388
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Pathologic Processes Trial Landscape
ClinicalTrials.gov lists 14 US studies indexed under Pathologic Processes, and 2 of those are currently open to recruitment — roughly 14% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Pathologic Processes shows 2 late-stage studies (Phase 3 and Phase 4 combined) alongside 3 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Pathologic Processes is led by University of Colorado, Denver with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 14 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Pathologic Processes?
PlainTrial tracks 14 US clinical trials for Pathologic Processes, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Pathologic Processes?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.